

Supplementary Material

Chemerin affects the expression of angiogenesis-related factors in the porcine endometrium during early pregnancy and the oestrous cycle: an *in vitro* study

Marta Kiezun^{A,}, Kamil Dobrzyn^B, Jacek Kiezun^C, Tadeusz Kaminski^A, and Nina Smolinska^A*

^ADepartment of Animal Anatomy and Physiology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, Oczapowskiego St. 1A, Olsztyn 10-719, Poland.

^BDepartment of Zoology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, Oczapowskiego Street 5, Olsztyn 10-719, Poland.

^CDepartment of Human Histology and Embryology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Warszawska St. 30, Olsztyn 10-082, Poland.

*Correspondence to: Marta Kiezun Department of Animal Anatomy and Physiology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, Oczapowskiego St. 1A, Olsztyn 10-719, Poland Email: marta.kiezun@uwm.edu.pl

Fig. S1. Exemplary blots for negative controls of primary rabbit IgG. Negative controls for rabbit IgG were performed exactly as positive blots (random protein samples used in the study), except for the use of non-immunised rabbit serum diluted in TBST instead of primary antibodies.



Table S1. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFA secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	30.80	0.000000
TREATMENT	2	3.18	0.048545
PHASE/STAGE*TREATMENT	8	2.28	0.033347
df	60		

Table S2. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFB secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	8.15	0.000026
TREATMENT	2	18.72	0.000000
PHASE/STAGE*TREATMENT	8	10.67	0.000000
df	60		

Table S3. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFC secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	33.51	0.000000
TREATMENT	2	7.68	0.001071
PHASE/STAGE*TREATMENT	8	5.32	0.000047
df	60		

Table S4. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFD secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	9.75	0.000004
TREATMENT	2	3.38	0.040693
PHASE/STAGE*TREATMENT	8	5.85	0.000016
df	60		

Table S5. The results of the two-way ANOVA analysis. The main factors and the interaction affecting PIGF secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	81.24	0.000000
TREATMENT	2	6.83	0.002132
PHASE/STAGE*TREATMENT	8	9.68	0.000000
df	60		

Table S6. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFR1 protein abundance in the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	30.79	0.000000
TREATMENT	2	0.41	0.665790
PHASE/STAGE*TREATMENT	8	8.71	0.000000
df	60		

Table S7. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFR2 protein abundance in the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	79.94	0.000000
TREATMENT	2	40.62	0.000000
PHASE/STAGE*TREATMENT	8	15.80	0.000000
df	60		

Table S8. The results of the two-way ANOVA analysis. The main factors and the interaction affecting VEGFR3 protein abundance in the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	229.70	0.000000
TREATMENT	2	100.96	0.000000
PHASE/STAGE*TREATMENT	8	29.96	0.000000
df	60		

Table S9. The results of the two-way ANOVA analysis. The main factors and the interaction affecting bFGF secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	123.32	0.000000
TREATMENT	2	1.17	0.316749
PHASE/STAGE*TREATMENT	8	2.23	0.037791
df	60		

Table S10. The results of the two-way ANOVA analysis. The main factors and the interaction affecting FGFR1 protein abundance in the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	20.48	0.000000
TREATMENT	2	5.10	0.009036
PHASE/STAGE*TREATMENT	8	14.41	0.000000
df	60		

Table S11. The results of the two-way ANOVA analysis. The main factors and the interaction affecting FGFR2 protein abundance in the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	42.93	0.000000
TREATMENT	2	30.53	0.000000
PHASE/STAGE*TREATMENT	8	56.57	0.000000
df	60		

Table S12. The results of the two-way ANOVA analysis. The main factors and the interaction affecting ANG-1 secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	42.93	0.000000
TREATMENT	2	30.53	0.000000
PHASE/STAGE*TREATMENT	8	56.57	0.000000
df	60		

Table S13. The results of the two-way ANOVA analysis. The main factors and the interaction affecting ANG-2 secretion by the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	90.50	0.000000
TREATMENT	2	17.20	0.000001
PHASE/STAGE*TREATMENT	8	8.50	0.000000
df	60		

Table S14. The results of the two-way ANOVA analysis. The main factors and the interaction affecting FGFR2 protein abundance in the endometrial tissue explants.

	df	F	p
PHASE/STAGE	4	41.54	0.000000
TREATMENT	2	17.67	0.000001
PHASE/STAGE*TREATMENT	8	9.29	0.000000
df	60		